	US 12,011,455 B2
	Enhancing plasmin activity to prevent soft tissue calcification
Jonathan Schoenecker, Nashville, TN (US); and Masato Yuasa, Nashville, TN (US)
Assigned to Vanderbilt University, Nashville, TN (US)
Appl. No. 16/085,973
Filed by Vanderbilt University, Nashville, TN (US)
PCT Filed Mar. 17, 2017, PCT No. PCT/US2017/023099 § 371(c)(1), (2) Date Sep. 17, 2018, PCT Pub. No. WO2017/161354, PCT Pub. Date Sep. 21, 2017.
Claims priority of provisional application 62/309,821, filed on Mar. 17, 2016.
Prior Publication US 2019/0076459 A1, Mar. 14, 2019
Int. Cl. C12N 15/11 (2006.01); A61K 31/713 (2006.01); A61K 38/00 (2006.01); A61K 38/36 (2006.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); A61P 21/00 (2006.01); A61P 43/00 (2006.01); C12N 15/113 (2010.01)

CPC A61K 31/713 (2013.01) [A61K 38/005 (2013.01); A61K 38/36 (2013.01); A61K 45/06 (2013.01); A61K 48/0016 (2013.01); A61P 21/00 (2018.01); A61P 43/00 (2018.01); C12N 15/113 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01)]

11 Claims

1. A method for reducing or preventing soft tissue calcification in a subject, comprising administering an effective soft tissue calcification reducing or preventing amount of, to a subject in need thereof, a plasmin(ogen) and a downregulator of at least one plasmin inhibitor; said subject having an acquired plasmin deficiency, and said subject having a severe injury;

wherein the at least one plasmin inhibitor includes α2-antiplasmin; and wherein the downregulator is an α2-antiplasmin antisense oligonucleotide;

further comprising administration of an antifibronolytic provided that the administration of the antifibronolytic is stopped within three days following said administration of at least one of plasmin(ogen) and a downregulator of at least one plasmin inhibitor.